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INTRODUCTION
Glaucoma is an optic neuropathy characterized by progressive 
structural and functional damage. Intraocular pressure (IOP) is the 
most important known risk factor for disease development and 
progression and until now the only modifiable one(1,2). That said, ef-
fective IOP reduction is the primary goal when it comes to glaucoma 
treatment(3).
When it comes to treatment options for IOP reduction, we have 
three main categories: topical medication, laser surgery, and inci-
sional surgery. Topical hypotensive medications are often used as a 
first-line treatment option, while incisional surgery is generally used 
when topical and laser treatments were not effective in achieving the 
target IOP. Although usually safe and effective, side effects from eye 
drops may occur, which can be local (e.g., conjunctival injection of 
prostaglandin analogues)(4) or systemic (e.g., cardiorespiratory effects 
of beta-blockers)(5). Furthermore, persistence and adherence studies 
on glaucoma show multiple barriers to an adequate treatment 
regimen with topical medication(6). Forgetfulness, medication cost, 
difficulty to instill eye drops, and patient’s misbelief that glaucoma is 
a blinding disease are frequently reported(6). As a result, self-reported 
treatment adherence rates are poor (ranging from 30 to 80%)(7,8), and 
many patients interrupt their newly prescribed medications in the 
first year of treatment(9,10). Therefore, an initial therapeutic alternative 
that minimizes ocular side effects and compliance issues could be 
very useful in clinical practice.
In this context, laser trabeculoplasty rises as an interesting the-
rapeutic option for open-angle glaucoma (OAG) cases, not relying 
on patient compliance. Argon laser trabeculoplasty (ALT) was first 
described in 1979 (Table 1)(11). The laser uses a blue-green (488 and 
514 nm) continuous wave argon laser with a 50 μm spot diameter and 
makes a disruption of the trabecular meshwork(12,13). In 1995, selective 
laser trabeculoplasty (SLT) was described. This melanin-target tissue 
sparing procedure uses a green (532 nm), Q-switched, frequency-
dou bled Nd:YAG laser(13). It is important to emphasize that ordinary 
YAG laser devices, commonly used for iridotomy or capsulotomy, 
cannot be used to perform SLT. 
Laser trabeculoplasty was initially described as an adjunctive 
treatment in eyes under topical hypotensive medications, often 
performed as a last alternative prior to incisional surgery in cases of 
uncontrolled disease(14). With the advent of SLT, there was a shift in 
the focus of most clinical studies related to laser trabeculoplasty(12,15). 
Looking carefully at the most recent publications, one can note that 
SLT has been evaluated as a first-line treatment option for IOP-lo-
wering in OAG patients without topical medication and less severe 
damage, with quite encouraging results(16,17).
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ABSTRACT
Although eye drops are frequently used as an initial treatment option for open 
angle glaucoma (OAG), side effects, and poor adherence, among others, may 
compromise treatment efficacy. In this scenario, laser trabeculoplasty is an in-
teresting therapeutic option for open angle glaucoma cases. Commonly used 
for many years as a last alternative prior to glaucoma incisional surgery, laser 
trabeculoplasty has been changing its indication after the advent of selective 
laser trabeculoplasty (SLT ). In the current review, we critically evaluated the 
published data regarding the use of laser trabeculoplasty as a first treatment 
option for open angle glaucoma patients. Studies using SLT as a first-line treat-
ment have encouraging findings. One-year efficacy results are comparable 
to those obtained with prostaglandin analogues, with a good safety profile. 
Although the laser´s effect is known to be transitory, recent data suggest it can 
be successfully repeated in cases with good response to the first SLT treatment.
Keywords: Glaucoma, open-angle/surgery; Trabeculectomy/methods; Lasers; In -
traocular pressure
RESUMO
Embora a terapia tópica seja frequentemente usada como primeira opção para o 
tratamento inicial do glaucoma de ângulo aberto (GAA), efeitos colaterais, baixa 
adesão, entre outros fatores podem comprometer a eficácia do tratamento. Nesse 
cenário, a trabeculoplastia a laser surge como uma opção terapêutica interessante. 
Comumente usada como última alternativa antes da cirurgia antiglaucomatosa 
incisional por muitos anos, a trabeculoplastia a laser tem sido indicada cada vez 
mais cedo com o advento da trabeculoplastia seletiva a laser (SLT ). Nessa revisão, 
nós avaliamos criticamente as publicações sobre trabeculoplastia a laser como 
primeira opção para glaucoma de ângulo aberto. Os estudos de SLT como primeira 
opção terapêutica têm apresentado dados animadores. Os resultados de um ano de 
acompanhamento mostram eficácia semelhante àquela obtida com análogos de 
prostaglandinas. Embora o efeito do laser seja transitório, estudos recentes sugerem 
que o procedimento pode ser repetido com sucesso nos casos que tiveram boa res posta 
ao primeiro tratamento com SLT.
Descritores: Glaucoma de ângulo aberto/cirurgia; Trabeculectomia/métodos; Lasers; 
Pressão intraocular
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In the current review, we critically evaluated the published data 
regarding the use of laser trabeculoplasty as a first treatment option 
for OAG patients. We conducted a PubMed search on March 19, 2016 
using the following keywords: “laser trabeculoplasty”, “open-angle 
glaucoma”, and “treatment”. All types of studies were considered for 
a first analysis. Only case-reports were excluded. Meeting abstracts 
were considered if presenting relevant and new data. Studies were 
then selected based on clinical relevance and contribution to the 
main focus of this review article. As most studies comparing ALT 
with SLT results were conducted in glaucoma patients under clinical 
treatment, we could not restrict our search criteria to studies using 
laser as first treatment option only. Therefore, we also included data 
from studies in patients already being treated by medication. 
TOPICS
Laser trabecuLopLasty as initiaL treatment for  
open angLe gLaucoma
The idea of using laser trabeculoplasty as the first treatment 
option for glaucoma is not recent nor restrict to SLT. The Glaucoma 
Laser Trial (GLT) was a multicenter study that evaluated the efficacy 
and safety of ALT as the primary therapy for glaucoma. In that study, 
patients with OAG were randomly assigned for initial treatment with 
ALT in one eye versus topical medication in the fellow eye. The main 
results showed that initial treatment with ALT was associated with 
a greater IOP reduction (mean difference of 1.2 mmHg) and better 
visual field outcomes (mean difference of 0.6 dB) than topical treat-
ment with timolol maleate. Additionally, ALT was at least as effective 
as timolol regarding stability of optic disc status over seven years(14). 
It is important to note that when GLT was carried out, neither prosta-
glandin analogs (PGA) nor SLT were available, thus limiting a straight 
comparison with more recent studies data(18). 
There are scant data in the literature comparing ALT vs SLT as the 
initial treatment options for OAG cases. In a relatively recent study 
by Gandolfi et al.(19), the authors reported that low power 360° SLT 
(repeated every year) was more effective than conventional ALT in 
achieving adequate IOP control in cases of ocular hypertension. On 
the other hand, most studies comparing ALT vs SLT for OAG (but 
not as a first treatment option) found similar success rates between 
the two laser modalities(20-22). However, when it comes to safety, the 
development of peripheral anterior synechiae seems to be a more 
frequent complication following ALT (incidence ranging between 
12% and 43% in previous studies) than SLT (rarely reported)(23,24). 
This procedure-related complication is influenced by technique and 
laser burns position (higher risk when laser is applied too posterior-
ly). Moreover, we believe that the ease of application (outcomes of 
physicians in training are comparable to those of glaucoma specia-
lists)(25) and the possibility of repeating the procedure with relatively 
good success rates (in cases with good response to the first SLT treat-
ment)(20,26) are two important advantages of SLT over ALT treatment. 
These factors have certainly contributed to the shift towards SLT use 
in the past decade and might explain the reason why ALT has not 
taken its place as a first line therapy. 
seLective Laser trabecuLopLasty as initiaL treatment for  
open angLe gLaucoma
Efficacy (IOP reduction)
In most studies, SLT has been investigated as a second-line treat-
ment option for OAG, being performed only after inappropriate 
response or intolerance to topical medication as an attempt to delay 
incisional surgery(27). As a result, there are few studies evaluating SLT 
as first treatment option. It is important to note that because the 
SLT effect is transitory, most of these studies are short-term (one to 
three years of follow-up). As PGAs are the first line clinical treatment 
to OAG, most studies compared SLT with PGA results in terms of IOP 
reduction. Looking carefully at safety and efficacy outcomes of these 
studies, we believe there is growing evidence that SLT can be used 
as a primary treatment for IOP-control in OAG cases(17,28-33). Table 2 
provides a summary of the main results of these studies.
Table 2. Studies of selective laser trabeculoplasty as the first treatment option for open-angle glaucoma and ocular hypertension
Study Design Key findings
Katz et al., (2012)16* SLT versus PGA
Total of 127 eyes
Mean IOP reduction of 25.7% 
Equally efficacy
FU: 12 months
Shazly et al., (2010)31 SLT-POAG and PXFG
Total of 37 eyes
Mean IOP reduction of 23% 
FU: 49 months
Mahdy (2008)29 SLT-OAG and OHT
Total of 35 eyes
Mean IOP reduction of 27.8% 
FU: 12 months
Mcllraith et al., (2006)17 SLT versus PGA
Total of 100 eyes
Mean IOP reduction of 31% 
Equally efficacy
FU: 12 months
Nagar et al., (2005)18* SLT versus PGA
Total of 167 eyes
In 360° SLT, 82% of eyes achieved a >20% IOP reduction
Equally efficacy (360° SLT vs PGA)
FU: 12 months
Melamed et al., (2003)33 SLT-OAG and OHT
Total of 45 eyes
Mean IOP reduction of 30% 
FU: 18 months
*= randomized studies.
OAG= open-angle glaucoma; OHT= ocular hypertension; PGA= prostaglandin analogs; POAG= primary open-angle glaucoma; PXFG= pseudoexfoliative glaucoma; SLT= 
selective laser trabeculoplasty; FU= follow up.
Table 1. Comparison of the different features of argon laser trabeculoplasty (ALT) and selective laser trabeculoplasty (SLT)
ALT SLT
Described in 1979 1995
Laser type Argon laser Q-switched, frequency-doubled Nd:YAG laser
Laser wavelength 488 and 514 nm (blue-green) 532 nm (green)
Spot diameter 50 μm 400 μm
Main action mechanisms Disruption of the trabecular meshwork Melanin-target tissue sparing
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At this point, we believe it is important to briefly discuss the main 
aspects of each study. When evaluating patients with OAG or ocular 
hypertension (OHT) treated with SLT, Melamed et al.(33) observed a 
≥19.6% IOP reduction in 89% of the patients, while Mahdy(29) found 
an IOP-reduction ≥25% in 77.1% of the cases. Overall, in an attempt to 
summarize IOP data from the available studies, we found that average 
absolute IOP-reduction following SLT as first treatment ranges from 
3 to 8 mmHg (percentage IOP reduction: 20% to 38%)(17,18,29,31,33,34). 
Other studies compared SLT versus PGA as a primary therapy, with 
similar efficacy between the two treatment modalities(16-18). When the 
extension of the laser was considered, PGA showed better results 
than 90° and 180° SLT, but not 360°(18). The efficacy of SLT was also 
evaluated in OAG eyes previously treated with glaucoma medication 
(monotherapy)(34). After a 30-day medication washout, SLT reduced 
IOP significantly, and IOP remained stable without medical therapy 
for 12 months(34). In addition, another study also evaluated SLT results 
after topical medication washout, and SLT 360° was effective [mean 
IOP reduction of 2.9 mmHg (40%) at 3 months and 2.1 mmHg (29.2%) 
at 6 months after the laser)(35). Besides that, another study that inclu-
ded eyes with pseudoexfoliative glaucoma (XFG) and primary open-
an gle glaucoma (POAG) revealed that SLT was effective as a primary 
treatment in both groups(31). 
Safety, duration, and repeatability
In general, SLT is considered a safe procedure(36). Serious compli-
cations are rare, but conjunctival redness and injection(33,37), transient 
IOP-increase(33,38,39), and mild anterior chamber reaction(37,38,40) are 
issues that the ophthalmologist and the patient should be aware of. 
Special attention must be given to sustained IOP increase(41), particu-
larly in higher risk patients, such as individuals with highly pigmented 
trabecular meshwork, multiple topical medications, and previous ALT 
treatment(42). Although loss of corneal endothelial cells has been re-
ported, it does not seem to be permanent, as recovery was observed 
after one month of the procedure(43). Additionally, anterior chamber 
volume and central corneal thickness decrease after SLT, retuning 
back to pre-SLT values after three months of the laser procedure(44). 
It is well established that the IOP-lowering effect of SLT decreases 
over time(38). Although it is usually attributed to the transitory effec-
tiveness of the procedure(21,38), the progressive trabecular meshwork 
dysfunction presented by glaucomatous patients along the years 
should also be considered(45). In this context, the possibility of re-
peating the laser procedure in eyes that lost IOP control over time 
became an important point to be investigated. Looking close at the 
more recent literature, one can note several studies showing that SLT 
can be repeated with similar efficacy when compared to the first SLT 
treatment. In these studies, POAG patients presented a significant 
IOP reduction at 1(46), 4(47), 6(46), 12(19,48), 15(46), and 24 months after re-
peating SLT(26,49). Corroborating these findings, Gandolfi and Ungaro 
demonstrated that repeated low power SLT as initial treatment pos-
tponed the initiation of medical therapy by a mean time of 6.2 years 
in patients with OHT(19). 
Success predictors of selective laser trabeculoplasty
As mentioned above, SLT does not work for everyone, as appro-
ximately one quarter of the patients do not achieve a significant 
IOP reduction(50). Therefore, the knowledge of success predictors is 
important for a proper indication and to estimate treatment out-
comes. Some success predictors are well established. For instance, 
better results are usually observed in patients with POAG(33,37,51-56), 
pseudoexfoliative glaucoma(31,40,57,58), and higher baseline IOP(40,41,46,47). 
A few isolated studies observed better results in eyes with thinner 
corneas(59), with earlier disease stage(60), and with higher refractive 
errors(52). Conversely, the use of PGA before laser was associated with 
a decreased IOP-lowering response(61), and SLT treatment had limited 
results in eyes with OAG receiving maximal-tolerable medical thera-
py(50,62). Other factors remain controversial, such as iridocorneal angle 
pigmentation(63,64) and advanced age(57,61). While some studies found 
a positive correlation between these factors and success rates, others 
did not. Regarding laser parameters itself, although good results 
have been recently reported with low power SLT (0.4 mJ per shot; 
repeated annually)(19), most studies have suggested better outcomes 
with higher power settings (energy per shot), more extensive laser 
treatment (360 degree), and greater number of shots(18,25,65,66).
There is also a strong correlation between SLT outcomes when 
we consider both eyes from the same patient(67). Shazly and Latina, 
evaluating eyes with OAG and OHT, found that in patients with SLT 
failure in the first treated eye, success odds in the fellow eye were 
less than 35%(67). Considering those with good response in the first 
treated eye, success rates of the fellow eye varied between 80% and 
100% in two different studies(68). In this context, it seems reasonable 
to perform SLT in one eye at a time. Not only because success odds 
of the second eye are remote in cases of failure of the first treated eye 
(and therefore the second eye should not be indicated in such cases), 
but also because the IOP values of the fellow untreated eye can be 
used to adjust SLT outcomes of the first treated eye (mitigating the 
influence of inter-visits IOP fluctuation and reducing the influence of 
regression to the mean). 
COMMENT 
During the course of OAG, patients will often need one or more 
medications to maintain IOP control and prevent progression of 
the disease. Ocular and systemic side effects of topical medications, 
forgetfulness, difficulties in handling the bottle and instill eye drops 
properly, and consequently poor compliance with the proposed 
medical regimen are important issues for clinicians when starting a 
therapy that will last a lifetime(6,8). Moreover, growing concern exists 
with drug-related chronic ocular surface inflammation, which may 
have a negative impact on success of a future filtration surgery(69). 
With this in mind, we believe it is reasonable to consider alternative 
treatments, such as laser therapy, as first-line treatment options(17,28,29). 
SLT has a good safety profile, does not rely on patient compliance, 
and has shown to be at least as effective as topical medications in 
lowering IOP as an initial treatment (for at least one year)(70-72) and 
can be repeated when IOP control is lost over time(19,46-48), possibly 
allowing patients to remain free of topical medication for years(73,74). 
In a chronic disease such as OAG, time is always a key parameter. We 
believe that SLT can be a way to buy it. Additionally, if this strategy 
does not work, topical medications can be promptly started. Never-
theless, it should be emphasized that studies are needed to evaluate 
whether SLT treatment would affect the efficacy of topical hypo-
tensive medications. All these things considered, SLT seems to be a 
reasonable, but still underused, form of initial treatment for patients 
with OAG and OHT.
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